Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Effectiveness of PFMT, Mirabegron, and Trospium in Older Women With UUI and High Fall Risk
NCT05880862Phase 1Completed
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirabegron and trospium in urge incontinence and overactive bladder (OAB) (3 arms), sponsored by The University of Texas Medical Branch at Galveston. Primary endpoints: Evaluability at 12 weeks, Clinical-Based Adherence at 12 weeks and 2 more. Started Sep 2023; status: completed.
02
Drugs
mirabegrontrospium
03
Conditions
urge incontinenceoveractive bladder (OAB)
Beyond the preview
Go deeper on NCT05880862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05880862.